Drugs / ABT-493/ABT-530
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT02243293 | Sep 2014 → Oct 2016 | chronic hepatitis C virus infection | AbbVie | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABT-493/ABT-530 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02243293 ↗ |
| Action | Inhibit | “The combination of ABT-493 (NS3/4A protease inhibitor) plus ABT-530 (NS5A inhibitor)” PMID 27456384 ↗ Jul 2016 |